{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer%2C+mCRPC",
    "query": {
      "condition": "Metastatic Castration-resistant Prostate Cancer, mCRPC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 231,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer%2C+mCRPC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T20:23:29.542Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04249947",
      "title": "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant",
        "Neoplasms by Histologic Type",
        "Neoplasms, Prostate",
        "Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Neoplasms",
        "Prostatic Neoplasms",
        "Genital Neoplasms, Male",
        "Urogenital Neoplasms",
        "Neoplasms by Site",
        "Prostatic Disease",
        "Salivary Gland Cancer",
        "Salivary Gland Tumor",
        "Adenoid Cystic Carcinoma",
        "Salivary Duct Carcinoma",
        "Mucoepidermoid Carcinoma",
        "Acinic Cell Tumor"
      ],
      "interventions": [
        {
          "name": "P-PSMA-101 CAR-T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Poseida Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-02-28",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 10,
      "location_summary": "Duarte, California • San Diego, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249947"
    },
    {
      "nct_id": "NCT02202447",
      "title": "Phase 1 of EC1169 In Patients With Recurrent MCRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EC1169",
          "type": "DRUG"
        },
        {
          "name": "EC0652",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Endocyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2014-05",
      "completion_date": "2018-11-29",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02202447"
    },
    {
      "nct_id": "NCT04898634",
      "title": "A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "JNJ-78278343",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 216,
      "start_date": "2021-07-13",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 3,
      "location_summary": "New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04898634"
    },
    {
      "nct_id": "NCT01692262",
      "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate-Resistant Prostate Cancer (mCRPC),",
        "Efficacy,",
        "Safety and Tolerability,",
        "Pharmacokinetics,",
        "Pharmacodynamics,",
        "Tumour Response."
      ],
      "interventions": [
        {
          "name": "Intermittent dosing of AZD5363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2012-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01692262"
    },
    {
      "nct_id": "NCT05125016",
      "title": "A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "REGN4336",
          "type": "DRUG"
        },
        {
          "name": "REGN5678",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 228,
      "start_date": "2021-11-30",
      "completion_date": "2030-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05125016"
    },
    {
      "nct_id": "NCT06402331",
      "title": "FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "FPI-2265",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fusion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 110,
      "start_date": "2024-03-05",
      "completion_date": "2031-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06402331"
    },
    {
      "nct_id": "NCT07493512",
      "title": "Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "Xaluritamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-28",
      "completion_date": "2030-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 12,
      "location_summary": "Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 7 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07493512"
    },
    {
      "nct_id": "NCT02826772",
      "title": "Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "GT0918",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suzhou Kintor Pharmaceutical Inc,",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2016-02-10",
      "completion_date": "2020-02-15",
      "has_results": false,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 6,
      "location_summary": "Towson, Maryland • Omaha, Nebraska • Las Vegas, Nevada + 3 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02826772"
    },
    {
      "nct_id": "NCT07164443",
      "title": "A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pasritamig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-87189401",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1203,
      "start_date": "2025-09-02",
      "completion_date": "2028-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 54,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 43 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07164443"
    },
    {
      "nct_id": "NCT05107674",
      "title": "A Study of NX-1607 in Adults With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer, Epithelial",
        "Gastric Cancer",
        "GastroEsophageal Junction (GEJ) Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic or Unresectable Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Malignant Pleural Mesothelioma (MPM)",
        "Triple Negative Breast Cancer (TNBC)",
        "Metastatic Urothelial Carcinoma",
        "Cervical Cancer",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Richter Transformation",
        "Microsatellite Stable Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "NX-1607",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nurix Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 345,
      "start_date": "2021-09-29",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-09-26T20:23:29.542Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107674"
    }
  ]
}